FibriCheck
FibriCheck provides FDA-cleared, smartphone-based heart rhythm monitoring using PPG technology and a clinically validated AI algorithm, serving healthcare providers, health systems, health plans, and patients globally.
- Company typePrivate
- Founded2014
- HeadquartersLimburg, Belgium
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What FibriCheck does
FibriCheck is an FDA-cleared medical device company that provides smartphone-based heart rhythm monitoring using photoplethysmography (PPG) technology. Founded in 2014 and operationally based in Limburg, Belgium with US headquarters in New York, the company enables patients to capture 60-second heart rhythm measurements via their existing smartphone camera, with results analyzed by a clinically validated AI algorithm reporting 98.5% accuracy for atrial fibrillation detection. The platform serves healthcare providers, health systems, health plans, and individual patients globally, with cumulative deployment of over 1.3 million patients monitored and 40 million rhythm strips analyzed to date, supported by more than 100 peer-reviewed publications and FDA 510(k) clearance as a Software-as-a-Medical-Device.
The product ecosystem consists of four integrated components: a patient-facing smartphone application, clinical reports with AF load and symptom correlation, a provider portal for patient data review and alert management, and an API enabling integration into existing Electronic Health Record (EHR), Remote Patient Monitoring (RPM), and population health platforms. Distribution spans direct enterprise sales to healthcare systems and health plans, API-based healthcare IT integration, and a direct-to-consumer smartphone app channel.
FibriCheck operates a B2B and B2B2C business model selling enterprise subscriptions to healthcare providers and payors, with deployment enabled through RPM reimbursement pathways. Pricing is quote-based and not publicly disclosed. The company has raised approximately $12.7M in disclosed funding across rounds from 2014 to 2020, with subsequent non-dilutive support from accelerator programs including MedTech Innovator (2024) and HeartX Cardiovascular Accelerator (2025).
FibriCheck firmographics
Firmographics- Name
- FibriCheck
- Legal name
- FibriCheck
- Website
- https://fibricheck.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- FibriCheck provides FDA-cleared, smartphone-based heart rhythm monitoring using PPG technology and a clinically validated AI algorithm, serving healthcare providers, health systems, health plans, and patients globally.
- Ownership category
- akta.pro rank
FibriCheck industry classification
Industry- Product category
- Remote Cardiac Monitoring Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)
- akta.pro secondary industries
- Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where FibriCheck is headquartered
LocationHeadquarters
- HQ city
- Limburg
- HQ country
- Belgium
- HQ region
- Europe
Offices1 record
Markets served
FibriCheck business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Remote Patient Monitoring (RPM) Reimbursement: FibriCheck operates within RPM reimbursement pathways, enabling healthcare providers and health systems to deploy the technology and bill through existing Remote Patient Monitoring codes. The company has reimbursement pathways already in place.
- Healthcare System & Health Plan Contracts: Direct contracts with healthcare systems, health plans, and providers for deployment of the heart rhythm monitoring ecosystem across clinical programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Quote-based enterprise pricing for healthcare organizations |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
FibriCheck product offering
Product offeringCore offering
FibriCheck provides an FDA-cleared, smartphone-based heart rhythm monitoring ecosystem that uses photoplethysmography (PPG) signals captured via the smartphone camera to detect atrial fibrillation and other arrhythmias. The offering combines a patient-facing mobile application for 60-second measurements, a clinically validated AI algorithm with 98.5% accuracy for AF detection, a web-based Provider Portal for clinical review and alert management, and an API for integration into EHRs, RPM platforms, and population health systems.
Product overview
FibriCheck is a complete heart rhythm monitoring ecosystem consisting of four integrated components: a patient-facing smartphone application (FibriCheck Mobile Application) that uses the device camera for 60-second PPG-based measurements, Clinical Reports delivering summarized rhythm analysis and AF load metrics, a Provider Portal for healthcare professionals to review data and manage alerts, and an EHR & Platform API enabling integration with existing healthcare IT systems. The ecosystem is powered by a clinically validated AI algorithm providing 98.5% accuracy for AF detection.
Differentiator
Problem solved
Functional benefit
Products and services
- FibriCheck Mobile Application
Quantifiable outcome
- 98.5% accuracy for AF detection
- +3 more outcomes
Companies that use FibriCheck
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
FibriCheck technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
FibriCheck partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- HeartX Cardiovascular AcceleratorcoreFibriCheck is supported by the HeartX Cardiovascular Accelerator, which announced the company among seven startup companies selected for its 2025 program focusing on innovative cardiovascular healthcare solutions.
- Mid and South Essex NHS Foundation TrustcoreNHS Foundation Trust using FibriCheck for remote heart rhythm monitoring, enabling patients to take readings at home and reducing unnecessary hospital visits. Lead Arrhythmia Nurse Specialist Sharon Toora quoted endorsing the technology.
- EHR & RPM Platform IntegrationscoreAPI-based integration partnerships with EHR systems, RPM platforms, and population health systems for seamless clinical workflow integration and deployment.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
FibriCheck competitors and assessment
Company assessmentBroad incumbents
- Fitbit (Google): Fitbit's PPG-based Irregular Heart Rhythm notifications and ECG app target the same general AF screening use case at the consumer/wellness tier, and Google's ownership adds AI/clinical research scale FibriCheck must compete with indirectly.
- Withings: Withings offers connected health devices including ECG-equipped smartwatches and BPM Core, with FDA-cleared AF detection. It competes for both the consumer heart-monitoring buyer and the clinician-prescribed remote monitoring use case.
- Apple (Apple Watch ECG): Apple Watch ships FDA-cleared PPG-based irregular rhythm and ECG features to a global consumer installed base. While not a clinical RPM platform, it dominates consumer AF detection mindshare and pressures FibriCheck's DTC channel.
Direct peers
- iRhythm Technologies: iRhythm's Zio patch provides ambulatory ECG monitoring with AI analysis, competing for the same cardiology-prescribed monitoring budget and clinical workflow that FibriCheck addresses with its PPG smartphone alternative.
- AliveCor: AliveCor's KardiaMobile is a smartphone/portable ECG device with FDA-cleared AF detection algorithms targeting the same patient-and-provider workflow that FibriCheck serves. It is the closest direct competitor in the smartphone-enabled cardiac rhythm monitoring space.
- Eko Health: Eko builds FDA-cleared AI-enabled cardiac monitoring tools (digital stethoscope + handheld ECG) with AI algorithms for AF and murmur detection, overlapping FibriCheck's clinical-grade AI cardiac screening positioning.
- Preventice Solutions (Boston Scientific): Preventice (now part of Boston Scientific) provides remote cardiac monitoring patches and services with AI-driven arrhythmia detection, competing head-to-head with FibriCheck for health system remote monitoring spend.
- BioTel (Philips): BioTel (formerly BioTelemetry, part of Philips) provides ambulatory cardiac monitoring services (MCOT, Holter) with AI-assisted reporting. It competes directly for cardiology practice and health system remote monitoring contracts.
Emerging players
- Cardiologs (Philips): Cardiologs offers AI-powered ECG analysis software used by clinicians for arrhythmia detection, integrated into Philips' cardiac monitoring portfolio. It overlaps with FibriCheck's provider-facing AI rhythm interpretation layer.
Regional players
- Huawei Health: Huawei smartwatches ship PPG-based heart rhythm and ECG features with regulatory approvals in Europe and parts of Asia. It is a comparable PPG-AF wearable play but does not directly target FibriCheck's clinical RPM channel in the US.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
FibriCheck social profiles
Digital presenceFibriCheck compliance and trust
Trust signalCompliance1 record
FibriCheck financial estimates
Financial estimateRevenue estimate
Valuation estimate
FibriCheck leadership team
Management profileNumber of profiles
Profiles4 records
FibriCheck funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FibriCheck M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FibriCheck
What does FibriCheck do?
FibriCheck provides an FDA-cleared, smartphone-based heart rhythm monitoring ecosystem that uses photoplethysmography (PPG) signals captured via the smartphone camera to detect atrial fibrillation and other arrhythmias. The offering combines a patient-facing mobile application for 60-second measurements, a clinically validated AI algorithm with 98.5% accuracy for AF detection, a web-based Provider Portal for clinical review and alert management, and an API for integration into EHRs, RPM platforms, and population health systems.
Is FibriCheck a public or private company?
FibriCheck is a private company. It is classified as venture growth investor backed and is currently operating.
When was FibriCheck founded?
FibriCheck was founded in 2014. It employs 11 to 50 people.
Where is FibriCheck based?
FibriCheck is headquartered in Limburg, Belgium, in the Europe region.
How does FibriCheck make money?
Two revenue lines are on record. Remote Patient Monitoring (RPM) Reimbursement is the primary driver. The others are healthcare System & Health Plan Contracts.
Who are FibriCheck's main competitors?
Broad incumbents on record are Fitbit (Google), Withings and Apple (Apple Watch ECG). Direct peers are iRhythm Technologies, AliveCor, Eko Health, Preventice Solutions (Boston Scientific) and BioTel (Philips). Cardiologs (Philips) is listed as an emerging player. Huawei Health is listed as a regional player.
Does FibriCheck have an API?
Yes. API-based integration into existing EHRs, RPM platforms, and population health systems. The API enables data exchange for rhythm monitoring results and clinical reports within healthcare provider workflows.
What industry is FibriCheck in?
FibriCheck's product category is Remote Cardiac Monitoring Software. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 334510 and its SIC code is 3845.